Ruxandra Teslo
Biotechnology
Why Biotech Companies Go to Australia to Test New Drugs
How America can get promising drugs into human trials faster, at lower cost, and without sacrificing safety
Read the full report
Biotechnology
Protect Human Subjects, Not Bureaucracy
How investigator choice in IRBs can improve ethical oversight
Read the full report
Biotechnology
Proxy Praxis: Why Validating an Endpoint Took 12 Years
Fragmented data and misaligned incentives are blocking faster clinical trials
Read the full report
Biotechnology
Proxy Praxis: How Surrogate Endpoints Can Speed Drug Development
A new series from the Institute for Progress
Read the full report
Emerging Technology
Biotech’s Lost Archive
How to fuel AI by unlocking the FDA’s knowledge of biotech failures
Read the full report
Biotechnology
The Case for Clinical Trial Abundance
A series of short papers outlining reform possibilities for America's clinical trials
Read the full report
